Jones D M, Atrash B, Ryder H, Teger-Nilsson A C, Gyzander E, Szelke M
Ferring Research Institute, Southampton University Research Centre, Chilworth, UK.
J Enzyme Inhib. 1995;9(1):43-60. doi: 10.3109/14756369509040680.
Much attention is currently focused on inhibitors of thrombin as potential anticoagulants. We have previously reported thrombin inhibitors based on fragments of fibrinogen containing a ketomethylene isostere at P1-P'1. We now expand on these early findings by reporting on tripeptide based inhibitors of thrombin containing arginine or lysine ketones at the C-terminus. A large variety of such ketones have been studied and compared in their ability to increase the thrombin time in human plasma. In the case of arginine or lysine ketones the order of activity (i.e. decreasing IC50 TT) was: alkyl ketones < beta-ketoesters < difluoro beta-ketoamides < alkyloxymethyl ketones < fluoroketones. Lysine analogues were generally found to be ca. ten-fold less active than their arginine counterparts. However, in the case of alpha-ketoesters the lysine derivatives were superior to all the types of arginine ketones studied (including the arginine alpha-keto ester derived thrombin inhibitor). A mechanistic explanation of the relative inactivity of the arginine alpha-keto ester derivative is proposed. All the highly electrophilic ketones were found to be slow-binding with thrombin.
目前,凝血酶抑制剂作为潜在的抗凝剂备受关注。我们之前报道过基于纤维蛋白原片段的凝血酶抑制剂,这些片段在P1 - P'1处含有酮亚甲基等排体。现在,我们通过报道基于三肽的凝血酶抑制剂来扩展这些早期发现,这些抑制剂在C末端含有精氨酸或赖氨酸酮。已经研究并比较了大量此类酮增加人血浆中凝血酶时间的能力。对于精氨酸或赖氨酸酮,活性顺序(即IC50 TT降低)为:烷基酮<β - 酮酯<二氟β - 酮酰胺<烷氧基甲基酮<氟代酮。一般发现赖氨酸类似物的活性比其精氨酸对应物低约十倍。然而,在α - 酮酯的情况下,赖氨酸衍生物优于所研究的所有类型精氨酸酮(包括精氨酸α - 酮酯衍生的凝血酶抑制剂)。提出了精氨酸α - 酮酯衍生物相对无活性的机制解释。发现所有高亲电酮与凝血酶的结合都很缓慢。